Treatment of cancer chemotherapy-associated anemia in Japan - Conditions and issues

Japanese Journal of Cancer and Chemotherapy

Volumn 41, Issue 4, 2014, Pages 426-431

  Yoshino, Ichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Blood transfusion; Chemotherapy; Chemotherapy induced anemia

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN DETERMINATION; HUMAN; JAPAN;

EID: 84903125864     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Tsuboi M, Ezaki K, Tobinai K, et al: Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, phase III, randomized, double-blind, placebo-controlled study. Jpn J Clin Oncol 39(3): 163-168, 2009.
2. Morishima Y, Ogura M, Yoneda S et al: Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: a randomized, double-blind, dose-finding study. Jpn J Cin Oncol 36(10): 655-661, 2006. (Pubitemid 44697560)
3. Suzuki Y, Tokuda Y, Fujiwara Y, et al: Weekly epoetin beta maintains hemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy. Jpn J Cin Oncol 38(3): 214-221, 2008. (Pubitemid 351419746)
4. Tonelli M, Hemmelgarn B, Reiman T, et al: Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer a meta-analysis. CMAJ 180(11): E62-71, 2009.
5. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98(10): 708-714, 2006. (Pubitemid 43821788)
6. U. S. Food and Drug Administration: Black Box Warning 2008. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/103234Orig1s5166- 103234Orig1s5266lbl.pdf
7. Rizzo JD, Brouwers M, Hurley P, et al: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Oncol Pract 6(6): 317-320, 2010.
8. Bokemeyer C, Aapro MS, Courdi A, et al: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2): 258-270, 2007. (Pubitemid 46127840)
9. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299(8): 914-924, 2009. (Pubitemid 351397066)
10. Bohlius J, Schmidlin K, Brillant C, et al: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373(9674): 1532-1542, 2009.
11. Ohashi Y, Uemura Y, Fujisaka Y, et al: Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci 104(4): 481-485, 2013.
12. http://www.mhlw.go.jp/stf/shingi/2r9852000001zb3y.html
13. Ludwig H, Van Belle S, Barrett-Lee P, et al: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40(15): 2293-2306, 2004. (Pubitemid 39348881)
14. Groopman JE and Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91(19): 1616-1634, 1999 (Pubitemid 29479929)
15. Kitano T, Tada H, Nishimura T, et al: Prevalence and incidence of anemia in Japanese cancer patients receiving outpatient chemotherapy. Int J Hematol 86(1): 37-41, 2007. (Pubitemid 47204488)
16. Barrett-Lee PJ, Bailey NP, O'Brien ME, et al: Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82(1): 93-97, 2000. (Pubitemid 30008965)
17. Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 168(21): 2377-2381, 2008.
18. Blajchman MA and Vamvakas EC: The continuing risk of transfusion- transmitted infections. N Engl J Med 355(13): 1303-1305, 2006. (Pubitemid 44465458)
19. http://www.mhlw.go.jp/new-info/kobetu/iyaku/kenketsugo/5tekisei3b.html
20. Vekeman F, Bookhart B, White J, et al: Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion 49(5): 895-902, 2009.
21. Weir MA, Gomes T, Winquist E, et al: Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agents. J Oncol Pract 8(3): 179-183, 2012.
22. NCCN Clinical Practice Guideline in Oncology v2, 2014 (24). http://www.nccn.org/professionals/physician-gls/pdf/anemia.pdf
23. ESA APPRAISE Oncology Program. https://www.esa-apprise.com/ESAAppriseUI/ ESAAppriseUI/restricted.jsp
24. Amato A and Pescatori M: Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev (1): CD005033, 2006.
25. Miller LD, Coffman LG, Chou JW, et al: An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 71(21): 6728-6737, 2011.
26. Song S, Christova T, Perusini S, et al: Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Res 71(24): 7628-7639, 2011.
27. http://www.mhlw.go.jp/stf/shingi/2r9852000000styz-att/2r9852000000su77. pdf